Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment

Journal of Neuroimmunology

Volumn 266, Issue 1-2, 2014, Pages 67-74

  Sadowska Bartosz, Izabela ^a   Adamczyk Sowa, Monika ^b   Gajewska, Agnieszka ^c   Bartosz, Grzegorz ^a,c  

^a UNIVERSITY OF RZESZÓW   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

Author keywords

AGEs; Carbonyl groups; Mitoxantrone; Multiple sclerosis; Oxidative protein modifications; Thioredoxin

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; BETA1A INTERFERON; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; INTERFERON BETA SERINE; KYNURENINE; MITOXANTRONE; N' FORMYLKYNURENINE; THIOREDOXIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; TREATMENT OUTCOME;

EID: 84891493865     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.11.005     Document Type: Article

References (36)

1. Adamczyk-Sowa M., Sowa P., Pierzchala K., Polaniak R., Labuz-Roszak B. Antioxidative enzymes activity and malondialdehyde concentration during mitoxantrone therapy in multiple sclerosis patients. J. Physiol. Pharmacol. 2012, 63:683-690.
2. Aldini G., Vistoli G., Stefek M., Chondrogianni N., Grune T., Sereikaite J., Sadowska-Bartosz I., Bartosz G. Molecular strategies to prevent, inhibit and degrade advanced glycoxidation and advanced lipoxidation end products. Free Radic. Res. 2013, 47(Suppl. 1):93-137.
3. Arif B., Ashraf J.M., Moinuddin A.J., Arif Z., Alam K. Structural and immunological characterization of Amadori-rich human serum albumin: role in diabetes mellitus. Arch. Biochem. Biophys. 2012, 522:17-25.
4. Chanvillard C., Millward J.M., Lozano M., Hamann I., Paul F., Zipp F., Dörr J., Infante-Duarte C. Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis. PLoS One 2012, 7:e39625.
5. Dalle-Donne I., Giustarini D., Colombo R., Rossi R., Milzani A. Protein carbonylation in human diseases. Trends Mol. Med. 2003, 9:169-176.
6. György B., Tóth E., Tarcsa E., Falus A., Buzás E.I. Citrullination: a posttranslational modification in health and disease. Int. J. Biochem. Cell Biol. 2006, 38:1662-1677.
7. Hentle T., Deppisch R., Beck W., Hergesell O., Hansch G.M., Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol. Dial. Transplant. 1999, 14:1968-1975.
8. Jamroz-Wisniewska A., Beltowski J., Stelmasiak Z., Bartosik-Psujek H. Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy. Acta Neurol. Scand. 2013, 127:e33-e36.
9. Johnson R., Baker J. Assay of serum fructosamine: internal vs external standardization. Clin. Chem. 1987, 33:1955-1956.
10. Kalousová M., Havrdová E., Mrázová K., Spacek P., Braun M., Uhrová J., Germanová A., Zima T. Advanced glycoxidation end products in patients with multiple sclerosis. Prague Med. Rep. 2005, 106:167-174.
11. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
12. Lim C.K., Brew B.J., Sundaram G., Guillemin G.J. Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int. J. Tryptophan Res. 2010, 3:157-167.
13. Ljubisavljevic S., Stojanovic I., Vojinovic S., Stojanov D., Stojanovic S., Cvetkovic T., Savic D., Pavlovic D. The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in sera and CSF. Neurochem. Int. 2013, 62:988-997.
14. Lovell M.A., Xie C., Gabbita S.P., Markesbery W.R. Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic. Biol. Med. 2000, 28:418-427.
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
16. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
17. Miller E., Mrowicka M., Saluk-Juszczak J., Majsterek I. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem. Res. 2011, 36:1012-1016.
18. Mironova R., Niwa T., Handzhiyski Y., Sredovska A., Ivanow I. Evidence for non-enzymatic glycosylation of Escherichia coli chromosomal DNA. Mol. Microbiol. 2005, 55:1801-1811.
19. Montú M.B., Arruda W.O., de Oliveira M.S., Ramina R. Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients. Arq. Neuropsiquiatr. 2005, 63:225-227.
20. Morrissey S.P., Le Page E., Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int. MS J. 2005, 12:74-87.
21. Moscarello M.A., Mastronardi F.G., Wood D.D. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem. Res. 2007, 32:251-256.
22. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15:16R-28R.
23. Reznick A.Z., Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 1994, 233:357-363.
24. Rice-Evans C., Diplock A.T., Symons M.C.R. Techniques in Free Radical Research (Laboratory Techniques in Biochemistry and Molecular Biology) 1991, Elsevier.
25. Robaszkiewicz A., Bartosz G., Soszyński M. N-chloroamino acids cause oxidative protein modifications in the erythrocyte membrane. Mech. Ageing Dev. 2008, 129:572-579.
26. Rossato L.G., Costa V.M., de Pinho P.G., Arbo M.D., de Freitas V., Vilain L., de Lourdes Bastos M., Palmeira C., Remião F. The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity. Arch. Toxicol. 2013, 87:1809-1820.
27. Sellner J., Kraus J., Awad A., Milo R., Hemmer B., Stüve O. The increasing incidence and prevalence of female multiple sclerosis - a critical analysis of potential environmental factors. Autoimmun. Rev. 2011, 10:495-502.
28. Seven A., Aslan M., Incir S., Altintas A. Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy. Folia Neuropathol. 2013, 51:56-64.
29. Stankiewicz J.M., Kolb H., Karni A., Weiner H.L. Role of immunosuppressive therapy for the treatment of multiple sclerosis. Neurotherapeutics 2013, 10:77-88.
30. Sternberg Z., Hennies C., Sternberg D., Wang P., Kinkel P., Hojnacki D., Weinstock-Guttmann B., Munschauer F. Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis. J. Neuroinflammation 2010, 7:72.
31. Sternberg Z., Ostrow P., Vaughan M., Chichelli T., Munschauer F. AGE-RAGE in multiple sclerosis brain. Immunol. Invest. 2011, 40:197-205.
32. Tasset I., Agüera E., Sánchez-López F., Feijóo M., Giraldo A.I., Cruz A.H., Gascón F., Túnez I. Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin. Biochem. 2012, 45:440-444.
33. Wållberg M., Bergquist J., Achour A., Breij E., Harris R.A. Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity. Eur. J. Immunol. 2007, 37:1986-1995.
34. Witko-Sarsat V., Friedlander M., Capeillère-Blandin C., Nguyen-Khoa T., Nguyen A.T., Zingraff J., Jungers P., Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996, 49:1304-1313.
35. Wu Y., Yang L., Zhong L. Decreased serum levels of thioredoxin in patients with coronary artery disease plus hyperhomocysteinemia is strongly associated with the disease severity. Atherosclerosis 2010, 212:351-355.
36. Zhang X.Y., Chen D.C., Xiu M.H., Yang F.D., Tan Y.L., He S., Kosten T.A., Kosten T.R. Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophr. Res. 2013, 143:301-306.